Cargando…
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)‐4 receptor α subunit (IL‐4Rα) of IL‐4 heterodimeric type I and type II receptors that mediate IL‐4/IL‐13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated...
Autores principales: | Li, Zhaoyang, Radin, Allen, Li, Meng, Hamilton, Jennifer D., Kajiwara, Miyuki, Davis, John D., Takahashi, Yoshinori, Hasegawa, Setsuo, Ming, Jeffrey E., DiCioccio, A. Thomas, Li, Yongtao, Kovalenko, Pavel, Lu, Qiang, Ortemann‐Renon, Catherine, Ardeleanu, Marius, Swanson, Brian N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496261/ https://www.ncbi.nlm.nih.gov/pubmed/32348036 http://dx.doi.org/10.1002/cpdd.798 |
Ejemplares similares
-
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2020) -
Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022) -
Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016) -
Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab
por: Davis, John D., et al.
Publicado: (2018) -
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)